PDCI is very excited to announce the promotion of Jennifer Haig to the position of Associate Director, HTA and Health Economics. This promotion is effective immediately.
Jen has been with PDCI for 18 months, and in that time has ... Read More
PDCI is excited to announce and welcome Kimberly Robinson as the newest member of the PDCI team. Kimberly will be joining as the Director of Pricing and Market Access effective April 1, 2019 and will be responsible for the leadership of PDCI’s Pricing/PMPRB team. She will be based in the ... Read More
Private health plans in Canada continue to implement many changes in their design and use of technology aimed at balancing the containment of health expenditures with the improvement of health and wellness. Yet what may be lost in any focus on cost-containment initiatives, is the opportunity for better management of ... Read More
Recognizing the increasing demand for PDCI expertise and the growing needs of our clients, we are proud to announce the addition of new staff in our Health Technology Assessment (HTA) and Reimbursement Strategy Teams.
Background
Our vision at PDCI is to be the most trusted and valued pricing and reimbursement strategic partner. ... Read More
PDCI Market Access is delighted to participate in the 4th Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders from pharmaceutical manufacturers, public/private payers, agencies, regulatory bodies and patient groups to analyze the key issues facing the industry in today’s complex environment. Participants will gain insights as ... Read More
On January 29, 2018, PDCI released a report critically evaluating Health Canada’s plan to change how patented medicine prices are regulated in Canada.
PDCI’s report - entitled Proposed Amendments to the Patented Medicines Regulations: A Critical Appraisal of the Cost-Benefit Analysis – includes perspectives on the Regulatory Impact Assessment Statement ... Read More
The mandatory public consultation process must be a tiresome inconvenience for Health Canada policy makers. At least that’s the perception from the release of its proposed amendments to the Patented Medicines Regulations (Regulations) and the accompanying Regulatory Impact Assessment Statement (RIAS) published in Canada Gazette Part I last week. Why ... Read More
Join us for a webinar on Dec 06, 2017 at 2:00 PM EST.
Register now!
Join PDCI’s Founder and Principal Consultant, Neil Palmer on this industry only webinar as he discusses the proposed amendments to the Patented Medicines Regulations as published in Canada Gazette Part 1 on December 2, 2017. What ... Read More
Proposed regulatory text of amendments to the Patented Medicines Regulations is published by the Governor-in-Council in Canada Gazette Part I (CG1) on December 2, 2017. Interested persons may submit comments on the proposed regulations within 75 days of publication in CG1 (by ... Read More
